Cochrane · systematic review · CD003575
Interventions for treating collagenous colitis
Kafil, TS, Nguyen, TM, Patton, PH, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
27
current version
GRADE rated
27
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 10 · 37%Low 17 · 63%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bismuth subsalicylate versus placebo for treating collagenous colitis
Population: Patients with collagenous colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Bismuth subsalicylate vs placebo | RR 10.8 [0.75, 155.93] | 1 study · 9 participants | Very low Downgraded: risk of bias, imprecision |
Histological response Bismuth subsalicylate vs placebo | RR 10.8 [0.75, 155.93] | 1 study · 9 participants | Very low Downgraded: risk of bias, imprecision |
Boswellia serrata extract versus placebo for treating collagenous colitis
Population: Patients with collagenous colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Boswellia serrata extract vs placebo | RR 1.64 [0.6, 4.49] | 1 study · 31 participants | Low Downgraded: imprecision |
Adverse events Boswellia serrata extract vs placebo | RR 1.88 [0.19, 18.6] | 1 study · 31 participants | Low Downgraded: imprecision |
Withdrawals due to adverse events Boswellia serrata extract vs placebo | RR 2.82 [0.12, 64.39] | 1 study · 31 participants | Low Downgraded: imprecision |
Budesonide versus mesalazine for treating collagenous colitis
Population: Patients with collagenous colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Budesonide vs mesalazine | RR 1.82 [1.13, 2.93] | 1 study · 55 participants | Low Downgraded: imprecision |
Histological response Budesonide vs mesalazine | RR 1.97 [1.24, 3.13] | 1 study · 55 participants | Low Downgraded: imprecision |
Adverse events Budesonide vs mesalazine | RR 0.69 [0.43, 1.1] | 1 study · 55 participants | Low Downgraded: imprecision |
Withdrawals due to adverse events Budesonide vs mesalazine | RR 0.09 [0.01, 1.65] | 1 study · 55 participants | Low Downgraded: imprecision |
Serious adverse events Budesonide vs mesalazine | RR 0.12 [0.01, 2.21] | 1 study · 55 participants | Low Downgraded: imprecision |
Mesalamine versus placebo for treating collagenous colitis
Population: Patients with collagenous colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Mesalamine vs placebo | RR 0.74 [0.44, 1.24] | 1 study · 62 participants | Low Downgraded: imprecision |
Histological response Mesalamine vs placebo | RR 0.86 [0.5, 1.47] | 1 study · 62 participants | Low Downgraded: imprecision |
Adverse events Mesalamine vs placebo | RR 1.26 [0.84, 1.88] | 1 study · 62 participants | Low Downgraded: imprecision |
Withdrawals due to adverse events Mesalamine vs placebo | RR 5.92 [0.7, 49.9] | 1 study · 62 participants | Low Downgraded: imprecision |
Serious adverse events Mesalamine vs placebo | RR 4.44 [0.49, 40.29] | 1 study · 62 participants | Low Downgraded: imprecision |
Mesalazine versus mesalazine + cholestyramine for treating collagenous colitis
Population: Patients with collagenous colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Mesalazine vs mesalazine + cholestyramine | RR 0.74 [0.5, 1.08] | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Mesalazine vs mesalazine + cholestyramine | RR 0.22 [0.01, 4.07] | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Prednisolone versus placebo for treating collagenous colitis
Population: Patients with collagenous colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Prednisolone vs placebo | RR 4.89 [0.35, 68.83] | 1 study · 11 participants | Very low Downgraded: risk of bias, imprecision |
Probiotics versus placebo for treating collagenous colitis
Population: Patients with collagenous colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Probiotics vs placebo | RR 2.29 [0.32, 16.13] | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Probiotics vs placebo | RR 0.57 [0.22, 1.5] | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |
Budesonide versus placebo for treating collagenous colitis
Population: Patients with collagenous colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response sensitivity analysis excluding Miehlke 2014 Budesonide vs placebo | RR 4.56 [2.43, 8.55] | 3 studies · 94 participants | Low Downgraded: risk of bias, imprecision |
Histological response sensitivity analysis excluding Miehlke 2014 Budesonide vs placebo | RR 4.15 [2.25, 7.66] | 3 studies · 94 participants | Low Downgraded: risk of bias, imprecision |
Maintenance of clinical response Budesonide vs placebo | RR 3.3 [2.13, 5.09] | 3 studies · 172 participants | Low Downgraded: risk of bias, imprecision |
Maintenance of histological response Budesonide vs placebo | RR 3.17 [1.44, 6.95] | 2 studies · 80 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Budesonide vs placebo | RR 1.18 [0.92, 1.51] | 5 studies · 290 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Budesonide vs placebo | RR 0.97 [0.43, 2.17] | 5 studies · 290 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Budesonide vs placebo | RR 1.11 [0.15, 8.01] | 4 studies · 175 participants | Very low Downgraded: risk of bias, imprecision |